Business

Pfizer and Moderna stocks tumble over anticipated low COVID-19 vaccination rate

By Gabrielle M. Etzel
Published September 18, 2023 9:23pm ET
Add Washington Examiner on Google
Pfizer and Moderna stocks tumble over anticipated low COVID-19 vaccination rate
A monitor displays Pfizer Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Friday, June 9, 2017. | (Michael Nagle/Bloomberg)

Pfizer, BioNTech, and Moderna stock prices fell precipitously on Monday as a result of anticipated low uptake rates for the updated COVID-19 vaccines.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Centers for Disease Control and Prevention COVID-19 FDA Pfizer Pharmaceutical Industry Vaccines